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Abstract
In patients with uremia, intact parathyroid hormone (PTH) measure-
ment appears to overestimate the biologically active hormone in
circulation. The recent description of the accumulation in these pa-
tients of a non-intact PTH form measured by the standard immunometric
assays, re-opened the question. In this study we submitted serum
samples from 7 patients with primary hyperparathyroidism (PHP) and
from 10 patients with hyperparathyroidism secondary to chronic renal
failure (SHP) to preparative HPLC in order to discriminate the molec-
ular forms measured by our currently used immunofluorometric assay
for intact PTH. The elution profile obtained with the HPLC system
showed two clearly defined peaks, the first one corresponding to a
lower molecular weight form, and the second to the intact PTH (1-84)
form. In patients with SHP the area under the curve for the first peak
(mean 29.5%, range 20.6 to 40.4%) was significantly greater than that
observed for patients with PHP (mean 15.6%, range 5.6 to 21.9%).
This confirms previous studies showing accumulation of molecular
forms of slightly lower molecular weight, presumably PTH (7-84), in
patients with SHP and, to a lesser extent, in patients with PHP. The real
necessity of assays that discriminate between these two molecular
forms is debatable.
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Parathyroid hormone (PTH) is a linear
peptide of 84 amino acids produced exclu-
sively by the parathyroid glands whose main
function is to regulate calcium levels in the
body. PTH circulates at very low concentra-
tions, and its measurement has evolved sub-
stantially since the first description of a ra-
dioimmunoassay that was capable of meas-
uring the concentration of this hormone in
normal and pathological conditions (1). The
early assays had carboxyl-terminal specific-
ity, being subsequently supplanted by amino-
terminal specific assays that presented better
clinical utility, especially in patients with
some degree of renal insufficiency (2). This
is due to the fact that the metabolically inac-
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tive carboxyl-terminal fragments accumu-
late as glomerular filtration rates decline,
and under these conditions an assay specific
for the biologically active amino-terminal
segment is more appropriate (3). These meth-
odological discussions seemed to have ended
with the description of the first immunometric
assay for PTH (4), that, recognizing the hor-
mone via two antibodies, one specific for the
carboxyl-terminal and other for the amino-
terminal sequence, could only measure the
intact hormone molecule. The high sensitiv-
ity of these assays, associated with their
remarkable specificity, provided a powerful
new tool for the diagnosis of PTH-related
diseases (5).
PTH structure and function studies have
shown some very interesting characteristics
of the molecule: one of them is that the
biological activity is concentrated in the
amino-terminal section of the molecule. In
fact, deletion of the first two amino acids
leads to a peptide that binds to the receptor
but is almost devoid of biological activity
(6). Studies based on hydrophilicity plots
and on the characteristics of most antibodies
produced against the amino-terminal seg-
ment of the molecule showed that the domi-
nant epitope of this section of the PTH mol-
ecule is located in the region between amino
acids 15 and 26 (7). This information, to-
gether with the clinical observation that in
patients with uremia intact PTH measure-
ments appeared to overestimate the biologi-
cally active hormone in circulation (8), indi-
cated that perhaps in these patients some
biologically inactive form was being meas-
ured by the “intact” hormone assays. In fact,
a loss of a small number of amino-terminal
amino acids will produce a biologically in-
active PTH form that theoretically will still
be recognized by the current intact assay
systems. Brossard et al. (9) were the first to
demonstrate that in patients with chronic
renal failure there was an accumulation of a
non-(1-84) PTH form measured by the im-
munometric assays. The importance of this
finding is evident, and the view that the
current immunometric assays for the intact
molecule were in fact measuring only the
biologically active PTH (1-84) form turned
out to be questionable.
In this study we submitted serum samples
from patients with primary hyperparathy-
roidism (PHP) and from patients with hyper-
parathyroidism secondary to chronic renal
failure (SHP) to high-performance liquid
chromatography (HPLC) in order to discrimi-
nate amongst molecular forms measured by
our currently used immunofluorometric as-
say for intact PTH (5).
Serum samples from 7 patients with sur-
gically proven PHP and from 10 uremic
patients under ongoing dialysis and with
SHP were submitted to the HPLC procedure.
The patients were treated at the Endocrinol-
ogy and Nephrology Clinics of Escola Pau-
lista de Medicina, Universidade Federal de
São Paulo. The PTH levels from the PHP
patients ranged from 76 to 1837 pg/ml (me-
dian 219 pg/ml) and the levels from the
patients with SHP ranged from 1036 to 1717
pg/ml (median 1324 pg/ml). Prior to the
chromatographic separation, serum samples
were pre-purified on Sep-Pak C18 cartridges,
and the adsorbed PTH was eluted and evapo-
rated under nitrogen. Samples were then
reconstituted in 1 ml of a solution of 0.1%
trifluoroacetic acid (TFA) in water. The chro-
matographic system used was based on that
described by Brossard et al. (9). Fifty micro-
liters was then injected into a Sephasil Pep-
tide C18 analytical column (4.6 x 250 mm;
Pharmacia Biotech, Uppsala, Sweden) and
eluted using a noncontinuous linear gradient
of acetonitrile (0-50% in 0.1% TFA in water,
applied at time = 10 min) run for 60 min in a
Waters HPLC system. One-milliliter frac-
tions were collected, and the selected tubes
were evaporated under nitrogen and recon-
stituted with 1 ml of PTH assay buffer. The
immunofluorometric assay employed (5) rec-
ognizes PTH via two epitopes: one carboxyl
terminal located around amino acids 68-69,
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and one amino terminal composed of amino
acids 15-26 (7). The area under the curve
was calculated using the Inplot software
(GraphPad Software, San Diego, CA, USA).
The elution profiles obtained by HPLC
for serum samples from one patient with
PHP and one with SHP are shown in Figure
1. Two elution peaks are clearly visible: a
first peak (tubes 41-43) and a larger second
peak (tubes 45-47). According to Lepage et
al. (10), the first peak corresponds to PTH
(7-84)  and the second to intact PTH (1-84).
Calculation of the area under the curve cor-
responding to the first peak for the 7 samples
from patients with PHP showed a mean of
15.6%, with a minimum of 5.6% and a maxi-
mum of 21.9%; for the patients with SHP the
mean area under the curve for the first peak
was 29.5%, with a minimum of 20.6% and a
maximum of 40.4% (Figure 2). Statistical
analysis showed that this difference was sig-
nificant (P = 0.0002, Mann-Whitney test).
Our findings agree with those described
by Brossard et al. (9) and Lepage et al. (10)
in that patients with SHP have a significant
proportion of hormone measured by intact
PTH assays that are not 1-84 molecules. This
finding could explain the lack of correlation
between the severity of bone abnormalities
and intact PTH levels observed in patients
with chronic renal failure (8). One of the
possible reasons for the finding of PTH lev-
els higher than expected in these patients
could be the presence of a molecular form
recognized by the routine intact assays but
lacking some amino-terminal amino acids.
Considering the specificity characteristics
of most of the assays in use, this finding is
not surprising, and the questions are: what
kind of PTH form is measured, when it ap-
pears, and what is the clinical importance of
these new molecular forms. Data have been
published showing that a correlation exists
between the decrease of glomerular filtra-
tion rate and the non-(1-84) PTH forms (11).
Nonetheless, the finding that these truncated
forms are present in patients with primary
Figure 1. Elution profiles obtained by HPLC for serum from a patient with primary hyper-
parathyroidism (A) and from a patient with hyperparathyroidism secondary to chronic renal
failure (B). PTH (1-84) = parathyroid hormone 1-84.
%
 A
U
C
 f
irs
t 
pe
ak
50
40
30
20
10
0
SHP PHP
Figure 2. Percent area under the
curve (AUC) corresponding to
the first chromatographic peak
for the 7 patients with primary
hyperparathyroidism (PHP) and
for the 10 patients with hyper-
parathyroidism secondary to
chronic renal failure (SHP).
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hyperparathyroidism and also in normal in-
dividuals (12), albeit at lower concentration,
indicates that the phenomenon is not exclu-
sive of patients with chronic renal failure.
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The recent description and characterization
of an assay exclusively specific for the active
whole PTH (1-84) form (13) confirmed val-
ues lower than those obtained by the tradi-
tional “intact” PTH assays (like ours) in
patients with hyperparathyroidism and in
normal individuals. The discrimination be-
tween normal and hyperparathyroid patients
does not appear to be significantly better
than that obtained with the “intact” assays,
but more data are necessary for this conclu-
sion. The recent description that the PTH (7-
84) fragment can have hypocalcemic actions
via a receptor different from the PTH/PTH-
related peptide receptor indicates that this
form is not simply a carboxyl-terminal frag-
ment (14). This finding is a strong argument
in favor of the necessity of measuring both
forms, at least in patients with chronic renal
deficiency and SHP, in order to have a more
complete evaluation of parathyroid function.
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